Systematic review of evidence on the clinical effectiveness of reflexology

Technical report prepared by Cochrane Australia

14 November 2024

Contents

[Scope of the technical report 4](#_Toc182446413)

[Appendix A. Study eligibility criteria, identification and selection 5](#_Toc182446414)

[Overview of Appendix A 5](#_Toc182446415)

[Appendix A1. Review questions and criteria for considering studies 6](#_Toc182446416)

[Primary objective to address the following question was 6](#_Toc182446417)

[Secondary objectives related to the following questions 6](#_Toc182446418)

[A1.1 Criteria for considering studies for this review 6](#_Toc182446419)

[A1.1.1 Types of studies 7](#_Toc182446420)

[A1.1.2 Types of participants 7](#_Toc182446421)

[A1.1.3 Types of interventions 8](#_Toc182446422)

[A1.1.4 Types of outcomes 9](#_Toc182446423)

[Appendix A2. Search methods for identification of studies 11](#_Toc182446424)

[A2.1 Electronic searches 11](#_Toc182446425)

[A2.2 Searching other resources 11](#_Toc182446426)

[Appendix A3. Methods for selecting studies 12](#_Toc182446427)

[A3.1 Selection of studies 12](#_Toc182446428)

[Appendix A4. Results of the search 14](#_Toc182446429)

[A4.1 Results of database search and other sources 14](#_Toc182446430)

[A4.2 Search strategies and results from each 14](#_Toc182446431)

[Appendix A5. Prioritisation process: methods used to refine the questions addressed in the synthesis 16](#_Toc182446432)

[Prioritisation of populations for inclusion in the synthesis 16](#_Toc182446433)

[Prioritisation and selection of outcomes for the synthesis 16](#_Toc182446434)

[Appendix A6. Final framework: synthesis questions and criteria for including studies in each synthesis 17](#_Toc182446435)

[Population groups included in the synthesis 17](#_Toc182446436)

[Population groups excluded from the synthesis 17](#_Toc182446437)

[Prioritised outcomes 17](#_Toc182446438)

[Appendix A7. Summary of inclusion decisions based on the final framework 19](#_Toc182446439)

[Appendix B. Data collection, analysis and interpretation of findings 20](#_Toc182446440)

[B1 Data extraction and management 20](#_Toc182446441)

[B1.1 Assessment of risk of bias of included studies 21](#_Toc182446442)

[B1.2 Measures of treatment effect 22](#_Toc182446443)

[B1.3 Unit of analysis issues 22](#_Toc182446444)

[B1.4 Dealing with missing data 23](#_Toc182446445)

[B1.5 Assessment of heterogeneity 23](#_Toc182446446)

[B1.6 Assessment of biases due to missing results 23](#_Toc182446447)

[B2 Data synthesis 24](#_Toc182446448)

[B2.1 Meta-analysis 24](#_Toc182446449)

[B2.2 Summary and synthesis when meta-analysis is not possible 24](#_Toc182446450)

[B2.3 Subgroup analysis and investigation of heterogeneity 24](#_Toc182446451)

[B2.4 Sensitivity analyses 25](#_Toc182446452)

[B2.5 Summary of findings tables and assessment of certainty of the body of evidence 25](#_Toc182446453)

[B2.6 Interpretation of findings (evidence statements) 27](#_Toc182446454)

[References for Appendix A and B 28](#_Toc182446455)

[Appendix C. Lists of studies considered for review 30](#_Toc182446456)

[Overview of Appendix C – separate file 30](#_Toc182446457)

[Appendix D. Extended results and citations for studies included in the evidence synthesis 31](#_Toc182446458)

[Overview of Appendix D – separate file 31](#_Toc182446459)

[Appendix E. Characteristics of studies included in the review 32](#_Toc182446460)

[Overview of Appendix E – separate files 32](#_Toc182446461)

[Appendix F. Risk of bias assessments 33](#_Toc182446462)

[Overview of Appendix F – separate file 33](#_Toc182446463)

[Appendix G. Differences between the protocol and the review 34](#_Toc182446464)

[Appendix H. Response to comments from the Methodological review 39](#_Toc182446465)

[Appendix I. Abbreviations 40](#_Toc182446466)

# 

# Scope of the technical report

This Technical Report includes a complete description of the methods for the review (Appendices A, B and G), results of the search and prioritisation process (Appendix A), and abbreviations used in the report (Appendix I).

It also includes an overview of Appendices C-F which are listed below but presented in separate files.

Appendices contained in this file are in light grey rows. Those in separate files are in blue rows.

|  |
| --- |
| Appendix A. Study eligibility criteria, identification and selection |
| Appendix B. Data collection, analysis and interpretation of findings |
| Appendix C. Lists of excluded studies, public submissions, studies awaiting classification, studies in the evidence inventory (1 file) |
| Appendix D. Extended results and citations for studies included in the evidence synthesis (1 file) |
| Appendix E. Characteristics of studies included in the evidence synthesis and evidence inventory (4 files) |
| Appendix F. Risk of bias assessments for studies contributing to meta-analyses (1 file) |
| Appendix G. Differences between the protocol and the review and methods not used |
| Appendix H. Response to methodological review |
| Appendix I. Abbreviations and list of measures |


# Appendix A. Study eligibility criteria, identification and selection

## Overview of Appendix A

Appendix A is comprised of Appendices A1-A7 (below). These Appendices report the methods (grey rows) and results (blue rows) from the first four stages of the review (Figure A, 1-4). These stages encompass the initial specification of questions to be addressed in the synthesis and criteria for including studies in the review, the specification and implementation of search methods, and the selection of studies. From this set of studies, we compiled information about the populations and outcomes addressed in randomised trials eligible for the review. This information was reviewed by the NHMRC, NTWC and NTREAP in order to confirm populations and outcomes for inclusion in the evidence synthesis.

|  |
| --- |
| Appendix A1. Review questions and criteria for considering studies for this review |
| Appendix A2. Search methods for identification of studies |
| Appendix A3. Methods for selecting studies |
| Appendix A4. Results of the search |
| Appendix A5. Prioritisation process: methods used to refine the questions addressed in the synthesis |
| Appendix A6. Final framework: synthesis questions and criteria for including studies in each synthesis |
| Appendix A7. Summary of inclusion decisions based on the final framework |

Appendices A1-A3 and A5 report the pre-specified methods from the protocol endorsed by NTWC, prospectively registered on the International prospective register of systematic reviews (PROSPERO IDCRD42023394291). Appendix A6 reports the framework that resulted from the prioritisation process shown in Figure A and described in Appendix A5. The framework was finalised prior to commencing data extraction (Figure A, panel 5). It defines the scope of the evidence synthesis and specifies the synthesis questions and associated PICO (population, intervention, comparator, outcome) criteria for including studies in each synthesis. Studies that met the eligibility criteria for the review but not the evidence synthesis are reported on the evidence inventory (Appendix E3).



**Fig A** | Staged approach for developing the questions and analytic framework for this review. 1Active comparators were not considered in the prioritisation process because of the large number of studies comparing reflexology to inactive comparators. 2 Separate tables are presented for studies included for the evidence synthesis (Appendix E1 and E2) and those in the evidence inventory (Appendix E3). Studies with ineligible populations, outcomes or active comparators are reported on the evidence inventory.

# Appendix A1. Review questions and criteria for considering studies

The overall objective of this systematic review is to examine the evidence for the clinical effectiveness of reflexology in preventing and/or treating injury, disease, medical conditions or preclinical conditions [1]. The questions for the review follow (framed as primary and secondary objectives). An initial analytic framework for the review was presented in the protocol to illustrate the breadth of questions and a possible structure for the synthesis, with indicative populations and outcome domains (Figure A1.1). The framework was refined through the prioritisation process (described in Appendix A5) leading to the final framework and criteria for including studies in the synthesis (Appendix A6). Outcomes listed in the objectives were agreed through the prioritisation process.


## Primary objective to address the following question was

1. What is the effect of *reflexology* compared to an inactive control (no intervention, sham, placebo, wait list control, or a co-intervention that was offered to both groups, or continuation of usual care) among people with any condition, pre-condition, injury or risk factor on each of the outcomes for which reflexology is commonly used (pain, sleep quality, fatigue, emotional functioning and mental health, health-related quality of life, physical function and global symptoms)?

## Secondary objectives related to the following questions

1. What is the effect of *reflexology* compared to an inactive control (no intervention, sham, placebo, wait list control, or a co-intervention that was offered to both groups, or continuation of usual care) on outcomes of importance for each underlying condition, pre-condition, injury or risk factor (for example, what is the effect on fatigue for people with cancer or advanced disease)?
2. What are the effects of *reflexology* compared to ‘*evidence-based’ treatments* (active comparators) on outcomes for each underlying condition, pre-condition, injury or risk factor?
3. What evidence exists examining the effects of reflexology compared to active comparators? (for inclusion in evidence inventory only, not the synthesis)

For objective 3, it was agreed that the planned comparison of the effects of reflexology to evidence-based treatments was not feasible because of the large volume of evidence contributing to objectives 1 and 2). Subsequent inspection of trials with an active comparator showed that the prespecified criteria for synthesis were not met (see ‘Types of interventions’). For these reasons, active comparators are listed in Appendix E1 (for studies that also contributed to objectives 1 and 2) and Appendix E3 (for studies that only contributed only to the evidence inventory). Other objectives were as stated in the protocol, with editing to include the outcome domains agreed through the prioritisation process. The final synthesis questions and criteria for including studies in each synthesis are presented in Figure A6.1.



**Fig A1.1 |** Initial analytic framework for the review showing example population groups and outcome domains for the Evidence Synthesis. The framework was informed by research on the outcomes (and underlying conditions) for which reflexology is commonly sought or prescribed in Australia, a scoping search of studies evaluating reflexology, the wider literature on reflexology, and consideration of frameworks for classifying disease and outcomes [2, 3].

## A1.1 Criteria for considering studies for this review

### A1.1.1 Types of studies

We included randomised controlled trials (RCTs) (including individually and cluster randomised, and cross-over trials).

Controlled trials in which the allocation sequence did not include a truly random element, was predictable, or was not adequately concealed from investigators were eligible as long as there was an attempt to have some kind of ‘randomisation’ to groups. Examples included studies that used methods for sequence generation based on alternation, dates (of birth or attendance at a clinic) and patient record numbers [4].

We excluded:

* Non-randomised studies of interventions (NRSIs).
* Studies described as ‘randomised trials’ or ‘controlled clinical trials’, but in which decisions about the allocation of participants to treatment groups were (1) made by clinicians or participants, or (2) based on the availability of the intervention. These studies lack any ‘attempt’ at randomisation and, as such, are likely to be at high risk of selection bias whereby participants may be selected into groups based on factors that are prognostic of outcomes (which may introduce confounding). For the purpose of the review, these studies were considered to be non-randomised studies and excluded.
* Studies for which available reports had not been peer reviewed (grey literature, including theses).

The decision to exclude non-randomised studies was informed by scanning results from a scoping search of the Cochrane Central Register of Controlled Trials (CENTRAL) (see A2.1.1), and results of a more limited search of PubMed using a resource on the National Institute of Health National Centre for Complementary and Integrative Health website (<https://www.nccih.nih.gov/health/providers/litreviews>). The scoping search of CENTRAL retrieved in excess of 400 potentially eligible trials, from which we anticipated a high proportion (100-200) would meet eligibility criteria for the review. Given the likely size and breadth of the evidence base, and the proposed structure for the synthesis, we considered that any effect of reflexology on health outcomes should be detectable from randomised trials. The inclusion of non-randomised studies was unlikely to increase certainty of the results from a body of randomised trial evidence of this size, or alter the conclusions of the review.

#### Date and language restrictions.

There were no restrictions on publication date.

Potentially eligible studies published in languages other than English were eligible for the review but not eligible for synthesis. In accordance with the protocol, these studies were included in the list of studies ‘Awaiting classification’ and coded according to whether they were likely to be eligible or whether eligibility could not be determined (see A3.1). The impact of excluding these studies was considered in the assessment of bias due to missing results and the certainty of evidence (see B1.6 and B2.5).

### A1.1.2 Types of participants

Studies involving participants with any disease, medical condition, injury, or preclinical condition were eligible for the review. This included healthy participants with clearly-identified risk factors (evident from study eligibility criteria or baseline data). There were no restrictions on age or other demographic factors.

We expected that studies would include participants that fall within broad population groups as indicated in the initial framework Figure A1.1. The population groups were based on ICD-11 codes, and encompass conditions identified in reflexology literature and the PRACI survey as often treated by reflexologists [5, 6]. Decisions about which populations to include in the evidence synthesis and how these populations would be grouped for synthesis were made through the prioritisation process (see Appendix A5) and reported in the final framework (see Appendix A6).

For trials in which reflexology was used for primary or secondary prevention, participants had to have a clearly-identified factor that put them at heightened risk of the condition that the intervention is intended to prevent compared to the population at large (e.g. a study that enrolled women in the community aged over 60 years in a trial of falls prevention would be ineligible unless the eligibility criteria required that the women had balance impairment at enrolment).

We operationalised this as follows:

* The risk factor(s) for the condition that reflexology was used to prevent was part of the eligibility criteria for the trial (e.g. symptoms of work-related anxiety in a trial aimed at preventing progression to an anxiety disorder)
* There was a direct link between the risk factor and the trial outcomes (i.e. an outcome that demonstrates progression to a diagnosable condition or pre-condition)

A provision was made to limit the review to specific populations if there were too many studies to be manageable. Only one conditions was excluded on this basis (see Appendix A6).

**Excluded populations**. Healthy populations seeking health improvement.

Studies that included both healthy participants and participants eligible for the review were to be included if separate data were available or a majority of participants met the review eligibility criteria [7]. No such studies were included.

### A1.1.3 Types of interventions

Reflexology was defined as a system of applying pressure to the outer extremities of the body (feet, hands, outer ears, and sometimes the lower limbs or face) on reflexes located within reflex maps of the body [8, 9]. Pressure is usually applied to the reflexes using the practitioner’s hand, fingers and thumbs and may involve a range of specific touch techniques (e.g., thumb- and finger-walking, hook and backup and rotating-on-a-point). The modality is non-invasive.

Because of the close similarity of reflexology with related modalities, and the likelihood of identifying studies in which the defining components of reflexology are incompletely reported, studies were included if

(a) the therapy was described as reflexology, or

(b) one of the recognised synonyms for reflexology (reflex therapy, zone therapy, reflex point therapy) was used, the description of the intervention in the study report included the defining features of reflexology (immediately above), and the intervention is clearly not another modality (e.g. not massage or acupressure).

Reflexology treatments were eligible irrespective of the method of reflexology, whether applied to feet or hands or other extremities (as above), whether provided by a reflexologist or another practitioner, the setting in which reflexology was delivered, the training or qualifications of the practitioner, the dose and duration of treatment, or with or without the use of neutral oils, talc or cream (i.e. without an active ingredient such as an essential oil). More details about each of these intervention features is provided under data extraction (see B1).

#### Comparisons

1. Reflexology versus any inactive control (no intervention, sham, placebo, wait list control, or a co-intervention offered to both groups, or continuation of usual care)
2. Reflexology versus ‘*evidence-based’ treatments* (active comparators) (included in the evidence inventory, not the synthesis, due to large volume of studies for comparison 1)
3. Reflexology versus other active comparators (for inclusion in evidence inventory only, not the synthesis – See below).

Any co-intervention was eligible (i.e. pharmacological or non-pharmacological). Usual care comparators were eligible if there was an explicit statement that indicated that participants could continue to access their routine care or therapy (including self-care). If a comparator labelled as ‘usual care’ involved a defined intervention (i.e. specific treatments and processes selected by the researchers), this was deemed to be either an active intervention (if restricted to the comparator group) or a co-intervention (if able to be accessed by both groups, e.g. continuation of a specific medication).

We sought advice from NTWC on the categorisation of comparators that involved massage or reflex points. Based on this advice, we categorised comparators that involved massage as 'inactive' if the description indicated a placebo for massage used in the reflexology group (e.g. "placebo heel massage", "control group received simple touch without pressure"). If the description indicated an active massage intervention (e.g. Swedish massage with description of specific techniques), the comparator was categorised as active. We categorised comparators that involved reflex points as 'inactive' if the description indicated that the reflex points were not specific to the condition/symptoms (as identified by the trialists).Active comparators eligible for the review were any pharmacological or non-pharmacological intervention, except natural therapies in other evidence evaluations. For comparison 2, a decision was made during the prioritisation step to include active comparators in the evidence inventory only (not the synthesis). This was initially due to the large volume of studies for comparison 1, but on closer inspection, the criteria for synthesis were not met for any evidence-based treatments (at least two low risk of bias studies with the same comparator, population and outcome).

Where a study included multiple arms, with at least one eligible comparator (e.g. a placebo control arm), we include all eligible comparisons.

***Excluded comparisons***. In line with the main review objective, which was to examine the effects of reflexology rather than the comparative effects of different reflexology treatments, we excluded head-to-head comparisons of reflexology. For example, we excluded studies where the only comparator was:

* another method of reflexology (e.g. Rwo Shur method versus the Ingham method)
* another reflexology touch technique or reflexology on a different part of the body (i.e. hand versus foot)
* a different dose (frequency, duration, schedule or combination thereof) of the same reflexology treatment,
* where the person administering the therapy has a different qualification, specialisation or skill level (e.g. reflexologists versus other health professional),
* or combinations of the above.

### A1.1.4 Types of outcomes

We considered for inclusion in the review any outcome that aligned with the reasons why reflexology is sought by patients and prescribed by practitioners. In principle, this could include any patient-important outcome that helps elucidate the effects of reflexology on an underlying condition or its symptoms, recovery, rehabilitation, or prevention of disease among people with specific risk factors or pre-conditions. Example outcome domains were shown in the initial analytic framework to illustrate the breadth of outcomes likely to be relevant across a wide range of conditions (Figure A1.1). The outcome domains were based on ICD-11 codes and the COMET outcome taxonomy [2, 3]. These systems provide a widely agreed and understood structure for categorising different outcomes.

Studies were included in the review irrespective of the outcome(s) measured, but the synthesis was limited to outcomes considered to be critical or important for each population group. Outcomes for inclusion in the synthesis were determined through the prioritisation process described in Appendix A5.

The outcome domains endorsed as critical or important for the synthesis were as follows (see Appendix A6 and Figure A6.1 for details).

* Pain
* Sleep quality
* Fatigue
* Emotional functioning and mental health
* Health-related quality of life
* Physical function
* Global symptoms

Nausea and vomiting was also endorsed as a critical/important outcome domain. Very few studies measured this outcome, and so these measures were considered under global symptoms rather than as a standalone domain.

From each study, we selected only one outcome per outcome domain for data extraction (results), risk of bias assessment and inclusion in the synthesis. In selecting outcomes for synthesis, we considered the outcome measure, timing of outcome measurement and data reported as follows.

***Outcome measures.***For each of these outcome domains, we considered for inclusion any measure of the outcome. Where studies reported multiple outcomes within an outcome domain, we used a population-specific hierarchy of outcomes measures to select the most relevant and valid outcome. The hierarchy of measures was proposed by the review team for an earlier natural therapies review and agreed through the prioritisation process.

***Outcome timing.*** Where trials reported outcomes measured at multiple timepoints, we selected the first measurement taken after the end of the reflexology intervention period (i.e. if reflexology was administered five times over a week, we took the first measure after the fifth administration).

***Data reported***

* When authors reported results for both change scores (change from baseline) and post-intervention (final) values, we selected results for final values.
* If data for the preferred measure was incompletely reported or uninterpretable, we selected another measure.

Excluded outcomes

* experience of care (e.g. satisfaction),
* safety,
* quality, and
* economic outcomes.

# Appendix A2. Search methods for identification of studies

### A2.1 Electronic searches

Studies were sought from the following databases: Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 2, 2023), PubMed, Emcare (Ovid), AMED (Ovid) and CINAHL (EBSCOhost). Separate searches of trial registry entries (e.g. ClinicalTrials.gov and WHO ICTRP) were not conducted for this review.

The primary source of studies was the Cochrane Central Register of Controlled Trials (CENTRAL), the most comprehensive source of published and unpublished reports of randomised trials. Most CENTRAL records are derived from regular searches of bibliographic databases, such as MEDLINE, Embase and CINAHL. Records from clinical trial registers (ClinicalTrials.gov and WHO International Clinical Trials Registry Platform) and the specialised registers maintained by Cochrane groups also make up a substantial proportion of records in CENTRAL. As part of Cochrane’s centralised search service, the major bibliographic databases and trials registers are searched monthly and, using a combination of automation and crowd screening, records deemed to be reports of randomised trials are added to CENTRAL [10].

The search strategy comprised variants of the text word 'reflexology' (e.g. reflexotherapy, reflex therapy, zone therapy, reflex point) and, where available, the relevant subject heading term. Additionally, we included records where the terms for feet, hands, ears or face were mentioned alongside reflex or massage. A broad study design filter for trials was applied (see Appendix A4).

Searches were run on 3 February 2023 and were not limited by language or publication status. Searches of PubMed and CINAHL were limited to the most recent 6 months and 12 months respectively (to address the lag between when records are processed by Cochrane and when they appear in CENTRAL), since these databases are part of Cochrane’s centralised search service and records deemed to be reports of randomised trials are automatically added to CENTRAL. We did not include Embase in these top-up searches since we deemed Embase to be a very unlikely source of unique studies of reflexology.

### A2.2 Searching other resources

The 31 randomised trials (34 reports) included in the systematic reviews for the 2015 evidence evaluation for reflexology were cross-checked against records retrieved by our search. Twenty-nine (29) were retrieved by the search and the remaining 5 were added to Covidence for screening (these 5 studies were reported in 11 papers).

We received 9 citations from the Department’s public call for submissions; 6 were retrieved by our search and 3 were added to Covidence for screening.

We searched PubMed for retracted publications, expressions of concern and published errata, as well as the Retraction Watch database.

In line with the protocol for this review, we did not examine the reference lists of included studies to identify additional trials (i.e. backward citation searching), nor did we conduct forwards citation searching (i.e. looking for studies that have cited included studies). Empirical studies assessing the value of reference checking (backward citation searching) as part of the systematic review process indicate that it is most useful for areas that are difficult to search electronically (new technologies, cross-disciplinary topics, complex interventions) or for which review authors aim to locate grey literature [11]. Forward citation searching is much less common in systematic reviews [12] and of questionable value [13]. Conducting forward citation searching for the large volume of reflexology studies we included in this review would have generated thousands of additional records to screen, with little evidence that we would identify unique studies. This would have resulted in significant time and cost implications [14]. Given the volume of included studies, it is unlikely that any studies missed through citation searching would impact the findings of the review.

# Appendix A3. Methods for selecting studies

### A3.1 Selection of studies

Records from CENTRAL, PubMed, AMED and Emcare were imported into EndNote and duplicates removed. All remaining records were imported into Covidence for screening. Records submitted through the Department’s public call for evidence were first deduplicated against these records, with the remaining unique records screened to confirm their eligibility (inclusion decisions were recorded for duplicate and non-duplicate records).

We piloted guidance for title and abstract screening on a sample of 50 records to ensure the eligibility criteria were applied consistently by two reviewers (MM, SM). We amended the screening guidance (but not the eligibility criteria) to enhance consistency. Trial register records retrieved from CENTRAL (i.e. from ClinicalTrials.gov and WHO ICTRP) were used to identify matching records for included studies. We did not screen the unmatched records (428) to ascertain the likely number of potentially eligible trials for which there was no full text report because of the high volume of studies eligible for the review and the feasibility of assessing the large number or registry records for eligibility for each of the meta-analyses. From experience from other natural therapies reviews, we judged it unlikely an analysis of registry records would contribute additional information that would change the review findings.

All records were reviewed independently by two reviewers at both the title and abstract screening and full-text review stages in Covidence. Disagreements at either stage of screening were resolved by consensus among members of the review team, and advice from NTWC regarding inclusion was not required.

The single protocol for an ongoing study confirmed as meeting the eligibility criteria, but for which results were not available in a published report, was reported in results for ongoing and unpublished studies (Appendix C5 and main report, section 4.1).

While screening full-text study reports in Covidence, we extracted the trial register and registry record number (if reported) into notes in Covidence. On completion of study report screening, the list of included studies was imported into Excel, as well as registry record search results. Code was written in Excel to match any registry record details in the included study notes (e.g. registry record number) with the registry records search results.

The following categories of studies were included in a list of ‘studies awaiting classification’ (Appendix C4):

* Studies that were only published as abstracts or for which a full report was not available (i.e. we did not seek further information from study authors to confirm eligibility).
* Studies for which a full report was available but the report was incomplete or ambiguous such that eligibility based on one or more PICO criteria or study design could not be confirmed.
* Studies confirmed as likely to be eligible, but for which no English language translation of the full-text publication was available.
* Studies for which eligibility could not be confirmed following translation of the title and abstract using Google translate (Figure A3.1.1)
* Studies for which there were concerns about data that could not be resolved from full report(s) (e.g. where there were important discrepancies in study characteristics or data reported across multiple publications from the same study).

Translate title + abstract

Is the study likely to be eligible?

Study unlikely to be eligible

Exclude

Unclear. translation provides insufficient information

List in 'Characteristics of studies awaiting classification'

Study likely (or very likely) to be eligible

List in 'Characteristics of studies awaiting classification'

**Fig. A3.1.1 |** Flowchart showing handling of studies in languages other than English (reproduced from NHMRC framework for natural therapies systematic reviews [15]).

Studies that did not meet the eligibility criteria were excluded and the reason for exclusion was recorded at full-text screening. Inclusion decisions were checked at data extraction, and for any studies identified as ineligible at this stage, the decision and exclusion reason were recorded in Covidence. These studies are included in a ‘Characteristics of excluded studies’ table in which the reason for exclusion is reported (Appendix C1).

The search and study selection steps are summarised in the PRISMA flow diagram in Appendix A7.

For studies that originated from the call for evidence, we recorded and reported exclusion decisions irrespective of whether the study was excluded during title and abstract screening or full text review. We documented the flow of these studies through the review in the PRISMA flow chart and in Appendix C2.

#### Dealing with duplicate and companion publications

Multiple publications to the same study (e.g. protocols, trial registry entries, trial reports) were identified and linked at the study selection stage in Covidence. Identification and linking of multiple reports were also checked at data extraction in REDCap [16, 17]. Each study was given a unique identifier and all linked records are cited in the final report. Records were matched using trial registry numbers. Where these were not available, we considered author names, trial name, trial location(s), number of participants, baseline characteristics and PICO.

#### Dealing with multiple study IDs

If multiple study reports resulted in the same study ID (Author Surname, Year) and were reporting the same study, the study ID for index report was given the suffix ‘.1’ after the Year (e.g. Ziyaeifard 2017.1), and the study ID for the secondary report was given the suffix ‘.2.’ (e.g. Ziyaeifard 2017.2).

If multiple study reports resulted in the same study ID (Author Surname, Year) and were reporting different studies, the study IDs for each study were given the suffix ‘a’, ‘b’, etc after the Year (e.g. Ebrahimi 2021a, Ebrahimi 2021b) to differentiate them.

# Appendix A4. Results of the search

### A4.1 Results of database search and other sources

The database searches retrieved 1799 records. After 560 duplicates were removed in EndNote and Covidence, 1239 records were screened at title/abstract. The search strategies for each database are given below. The PRISMA flow diagram in Appendix A7 summarises inclusion decisions following title/abstract screening.

From the 'other sources' we searched we identified 8 unique citations: 5 from the 2015 evidence evaluation for reflexology and 3 from the public submissions.

#### 2015 evidence evaluation for reflexology

The 2015 overview of 18 systematic reviews investigating the effects of reflexology comprised 31 unique reflexology trials (34 records). From these citations, we screened 11 unique records not retrieved by our search of which one was excluded based on title (acupressure intervention), one was ineligible (published in a thesis) and three were listed as awaiting classification (2 in languages other than English, one with multiple reports where we could not determine whether data were from a single trial or several independent studies).

#### Public submissions

There were 9 records received from the Department’s public call for evidence. Eligibility decisions for all 9 records are reported in Appendix C2. Three (3) of the 9 submissions were unique records, none of which were eligible (two were studies of mechanism of action, one was a systematic review of 44 non-randomised studies.

#### Retractions and published errata

The PubMed search for reflexology was combined with the following search string, across all years: (Expression of Concern[PT] OR Corrected and Republished Article[PT] OR Published Erratum[PT] OR Retracted Publication[PT] OR Retraction of Publication[PT]). We did not identify any errata or published retractions.

### A4.2 Search strategies and results from each

#### Cochrane Central Register of Controlled Trials (Issue 2, 2023)

|  |  |  |
| --- | --- | --- |
| # | Search strategy | Results |
| 1 | ((reflexolog\* or reflexotherapy or "reflex therapy" or "zone therapy" or "reflex point" or "reflex points"):ti,ab,kw) (Word variations have been searched) | 734 |
| 2 | ((foot or feet or plantar or hand\* or ear or ears or face) NEAR/3 (reflex or massage\*)):ti,ab,kw (Word variations have been searched) | 673 |
| 3 | #1 or #2 [in Trials] | 1207 |
| 4 | #3 excluding 372 register records from ICTRP and 134 from ClinicalTrials.gov | 701 |

#### PubMed (3 February 2023)

Limited to most recent six months (August 2022 – current)

(reflexolog\*[TIAB] OR reflexotherapy[TIAB] OR "reflex therapy"[TIAB] OR "zone therapy"[TIAB] OR "reflex point\*"[TIAB] OR ((reflex\*[TIAB] OR massag\*[TIAB]) AND (foot[TIAB] OR feet[TIAB] OR plantar[TIAB] OR hand\*[TIAB] OR ear[TIAB] OR ears[TIAB]))) AND ((Clinical Trial[PT] OR trial OR random\* OR placebo) NOT systematic[SB]) AND 2022/08/01:3000[EDAT]

Records retrieved = 36

Limited to Pubmed-not-MEDLINE subset (all years)

(reflexolog\*[TIAB] OR reflexotherapy[TIAB] OR "reflex therapy"[TIAB] OR "zone therapy"[TIAB] OR "reflex point\*"[TIAB] OR ((reflex\*[TIAB] OR massag\*[TIAB]) AND (foot[TIAB] OR feet[TIAB] OR plantar[TIAB] OR hand\*[TIAB] OR ear[TIAB] OR ears[TIAB]))) AND ((trial OR random\* OR placebo) NOT systematic[SB]) AND pubmednotmedline[SB]

Records retrieved = 174

#### AMED via Ovid (1985 to January 2023)

|  |  |  |
| --- | --- | --- |
| # | Search strategy | Results |
| 1 | exp Reflexology/ | 272 |
| 2 | (reflexolog$ or reflexotherapy or reflex therapy or zone therapy or reflex point$ or  ((reflex$ or massag$) adj3 (foot or feet or plantar or hand$ or ear or ears or face))).af. | 556 |
| 3 | exp Clinical Trials/ | 5076 |
| 4 | (trial or random$ or placebo or (control adj5 group$)).af. | 35792 |
| 5 | (1 or 2) and (3 or 4) | 146 |

#### Emcare via Ovid (1995 to 2023 Week 04)

|  |  |  |
| --- | --- | --- |
| # | Search strategy | Results |
| 1 | exp Reflexology/ | 575 |
| 2 | ((reflexolog$ or reflexotherapy or reflex therapy or zone therapy or reflex point$ or ((reflex$ or massag$) adj3 (foot or feet or plantar or hand$ or ear or ears or face))).af. | 1654 |
| 3 | exp Clinical Trial/ | 355748 |
| 4 | (trial or random$ or placebo or (control adj5 group$)).af. | 1014200 |
| 5 | (1 or 2) and (3 or 4) | 639 |

#### CINAHL Plus via EBSCOhost (3 February 2023)

|  |  |  |
| --- | --- | --- |
| # | Search strategy | Results |
| 4 | S1 OR S2 OR S3 Limiters – Publication Year: 2022-2023 | 103 |
| 3 | TX ((foot or feet or plantar or hand\* or palm\* or wrist\* or ear or ears or face) N3 (reflex or massage\*)) | 941 |
| 2 | TX reflexolog\* or reflexotherapy or "reflex therapy" or "zone therapy" or "reflex point" or "reflex points" | 1211 |
| 1 | (MH "Reflexology") | 861 |

# Appendix A5. Prioritisation process: methods used to refine the questions addressed in the synthesis

Decisions about the final synthesis questions and criteria for including studies in each synthesis were made through the prioritisation process in Figure A. The process was designed to minimise bias in the selection of results for inclusion in the synthesis while ensuring coverage of populations and outcomes most relevant to the Australian context.

In brief,

* we screened studies against the review eligibility criteria and collated deidentified, aggregate information about the populations and outcomes addressed in included studies (no bibliographic information, titles, details about the number of studies, participants, methodological quality or results),
* we proposed a list of outcome domains relevant to each population, and possible exclusions to limit scope and ensure a focus on patient-relevant outcomes, and then
* NTWC, with input from NTREAP, prioritised outcome domains and population groups (below) for the synthesis (Figure A6.1).

### Prioritisation of populations for inclusion in the synthesis

Studies involving any population were eligible for the review (except for the specific exclusions listed in A1.1.2), however a provision was made in the protocol to limit the populations (conditions) for inclusion in the synthesis if the number of eligible studies was unmanageable. Because of the large number of eligible studies, NTWC reviewed and accepted a proposal to exclude one population (hypertension) from the synthesis. Hypertension was not identified in the PRACI survey as commonly treated by practitioners in Australia, and was addressed in only two studies (see A6 for exclusions).

### Prioritisation and selection of outcomes for the synthesis

To prioritise the most important outcomes for this review we did the following.

* We compiled a list of population-specific outcomes from included studies.
* Outcomes in the list were categorised by the outcome domains and population groups in the initial framework Figure A1.1. Outcomes that fell outside the proposed outcome domain were also listed.
* NTWC was asked to indicate whether each of the listed outcome domains were important for understanding the effects of reflexology for each population. Only prioritised outcome domains were considered in the synthesis.

***Outcome selection.*** From each study, we selected only one outcome per outcome domain for data extraction (results), risk of bias assessment and inclusion in the summary and synthesis.

For each outcome domain, we anticipated that there would be considerable multiplicity of results arising within and across studies from reporting of:

1. multiple outcomes within a domain (e.g. pain intensity on average, pain intensity at its worst),
2. multiple measures of an outcome domain (e.g. visual analogue scale score and McGill),
3. multiple timepoints, or
4. combinations of all three.

To determine which results to select we proposed using a hierarchy of outcomes measures developed for another natural therapies review (aromatherapy). Where possible, the outcome hierarchy was based on hierarchies used in Cochrane reviews, core outcome sets and systematic reviews of the measurement properties of instruments.

We used the standardised mean difference (SMD) as an effect measure which enabled results to be combined for meta-analysis when different outcome measures were used. This ensured that any study that reported an outcome within a domain could be included in the analysis (see B1.2 and B2.1).

# Appendix A6. Final framework: synthesis questions and criteria for including studies in each synthesis

Figure A6.1, shows the final analytic framework for the evidence summary and synthesis. The framework provides a guide to the structure of the synthesis and reporting of results (see caption for details). There is a meta-analysis for each outcome domain with population groups within as listed.

### Population groups included in the synthesis

Some refinements were made to the populations listed in the initial framework (column 1). We separated acute conditions and indications from chronic and longer-term conditions, to provide greater clarity about which outcomes were relevant. For example, for people undergoing hysterectomy, the population was categorised as ‘surgery’ rather than ‘chronic’ if treatment was focused on outcomes in the acute perioperative period rather than longer-term outcomes. In turn, health-related quality of life, fatigue and physical function were considered relevant only to populations with chronic or longer-term conditions receiving reflexology treatment over weeks or longer (not days) and where outcomes were measured in a timeframe likely to detect meaningful improvement (i.e. generally 4 weeks or more from commencement of reflexology).

### Population groups excluded from the synthesis

Given the number of studies included in the review, agreement was reached through the prioritisation process to exclude studies of reflexology for the treatment of hypertension (2 studies). The characteristics of studies excluded from the synthesis on this basis are reported in Appendix E3, and a list of references for the studies and reasons for exclusion are in Appendix C3.


### Prioritised outcomes

The outcome domains specified in the initial analytic framework were endorsed, and the outcomes relevant to each population groups were agreed with some refinement to the presentation in the initial framework. Outcome domains and population specific outcomes that were not prioritised for any population were:

* physiological function, signs and symptoms (e.g. blood pressure, heart rate) including postoperatively,
* biomarkers of stress,
* biomechanical outcomes,
* outcomes related to labour and childbirth (e.g. labour stress)
* lactation outcomes (e.g. time to first colostrum, breastmilk volume)
* exercise volume and tolerance (chronic obstructive pulmonary disease)
* foot impairment indicators (diabetes e.g. hair growth, integrity of skin)
* micturition frequency (overactive bladder)
* oedema volume (pre-eclampsia)
* ovulation (fertility)
* hyperbilirubinemia outcomes (bilirubin level, duration of phototherapy)

Characteristics of studies among populations eligible for the synthesis that only measured these ineligible outcomes (as determined from included reports) are reported on the evidence Inventory (Appendix E3).

***Outcome measures and timepoints.*** The hierarchy of outcomes measures developed for the review of aromatherapy was endorsed for use in the reflexology review. First measure after the end of the intervention period was endorsed as the preferred timepoint (i.e. if reflexology was administered two times per week over 4 weeks, we took the first measure after the second administration in the 4th week).

****

**Fig A6.1** | Final analytic framework for the review as agreed through the prioritisation process (Appendix A5).   
Columns 1 to 3 show the populations and outcome domains eligible for the evidence synthesis. Column 3 shows the populations and outcome domains for which studies were available. Results are reported for each population group in the section of the main report indicated in column 2. Study-level data and meta-analyses are presented in the corresponding forest plot in each section. Population groups are those reported by practitioners of reflexology as often treated in the PRACI survey. \*conditions not reported in PRACI survey but included for completeness.

# Appendix A7. Summary of inclusion decisions based on the final framework

The flow of studies through the review is summarised in Figure A7.1, the PRISMA flowchart. Inclusions for each synthesis and the evidence inventory are reported in Figure A6.1 and described in the main report.

A diagram of a company

Description automatically generated with medium confidence

**Fig. A7.1** | PRISMA diagram showing the flow of studies through the review (reproduced from main report Fig. 4.1.1). \* In addition to records from the search, 9 public submissions were received and screened, of which 3 were unique records (see Appendix C2). \*\* Studies are the unit of interest in the review. For each study there may be multiple reports. †Exclusion of studies reported in the evidence inventory from synthesis was agreed through the prioritisation process (Fig A1; Methods appendix A5, A6). CoIS: characteristics of included studies.

# Appendix B. Data collection, analysis and interpretation of findings

## B1 Data extraction and management

Study data were collected and managed using REDCap electronic data capture tools hosted at Monash University [16, 17]. The form for extracting results data was developed by the review biostatistician (JM). The form was developed for use by our team for the natural therapies reviews and had been applied to over 200 trials in the first review we conducted. Extensive pre-testing of the data extraction and coding form had been done on studies in earlier reviews with revisions made to the data extraction form to maximise the completeness, accuracy, and consistency of data collection. Data extractors were trained in the use of the form, and initial coding and extraction was reviewed with feedback provided prior to continuing with further studies. Frequently asked questions were logged with responses shared with all extractors to promote concordance. Quantitative data was reviewed with the review biostatistician (ST or JM).

To streamline the allocation of studies for analysis and selection of outcomes (when multiple results were reported for a domain), we implemented a two-step process for data extraction. In the first step, studies were triaged by a senior author (MM or SB). For each study we coded population groups, outcome domains and comparisons, and allocated the study to analyses according to the analytic framework for the review. We listed all outcomes measured and selected the outcomes for inclusion in the synthesis according to our pre-specified decision rules. The triage process included confirmation of study eligibility and basic checks of methodology (e.g. confirming that a trial met the minimum requirements for randomisation). Studies that were eligible for the review, but not the synthesis, were assigned to the evidence inventory at triage.

For each included study, one review author (KJ, PN, LK) then extracted study characteristics and quantitative data using the data extraction and coding form. A second author (MM) independently verified the data. All queries related to the quantitative data were referred to a biostatistician, who also extracted more complex data and that from crossover trials. Discrepancies were resolved through discussion with a senior author (SB, JM) if agreement could not be reached or for more complex scenarios.

Where available, we extracted information relating to the characteristics of included studies and results as follows.

1. Study identifiers and characteristics of the study design

* Study references (multiple publications arising from the same study were matched to an index reference; code as index paper, protocol, registry entry, results paper 1, 2, …)
* Study name, location (country), enrolment dates (not reported by most studies), and trial registration number
* Study design (categorised as ‘individually randomised’, ‘cluster randomised’, ‘crossover’, or ‘other’); whether clustering was likely to arise because of the way reflexology was delivered (e.g. at a regular clinic such as for haemodialysis; this information was used to determine which risk of bias tool to use for assessment).
* Funding sources and funder involvement in study, financial and non-financial interests declared by investigators, potential conflicts (reviewer judgment), ethics approval.

1. Characteristics of each intervention group (including comparator groups)

* Characteristics of the intervention covering domains of the Template for Intervention Description and Replication (TIDieR) checklist [18]
* Reflexology intervention goal (coded, for example: relieve surgery-related side effects, treat underlying condition, prevent a condition among people with risk factors)
* Coding of comparators (e.g. inactive – sham reflexology, inactive – placebo, inactive – no intervention, inactive control – cointervention delivered to both groups)
* Number of participants: randomised to each group, at follow up for selected outcome, and included in analysis and reasons for loss to follow-up

1. Characteristics of participants

* Participant eligibility criteria (verbatim; precis of key criteria to characterise population)
* Participant characteristics: age (e.g. mean, median, range), sex
* Population group: coded using categories specified in the final analytic framework for the review (e.g. chronic musculoskeletal pain, headache or migraine, cancer and advanced disease (not amenable to cure), surgery, procedures, pregnancy, labour and childbirth, chronic insomnia, sleep disturbance, dementia, mental distress)
* Condition: specific underlying condition as described in study (e.g. haematological tumours; rheumatoid arthritis), including information about severity (if relevant) and closest ICD-11 code.
* Treatment/procedure: applied to studies in which reflexology was administered for the relief of symptoms or side effects of a treatment or procedure for an underlying condition (e.g. radiotherapy; bone marrow biopsy). Could include pharmacological treatment (e.g. chemotherapy), surgical, diagnostic or other procedures (as described in study).
* Other characteristics of importance within the context of each study

1. Outcomes assessed and results

* Outcomes measured (list of all outcomes categorised as ‘eligible’ or ‘ineligible’ and categorised according to the final analytic framework; measures used for each)
* For outcomes selected for inclusion in the summary and synthesis of results:
  + Outcome domain: categorised according to the outcome domains specified in the final analytic framework for the review (e.g. pain, sleep quality, fatigue, emotional functioning and mental health, health-related quality of life, physical function, global symptoms)
  + Outcome as described in the included study (verbatim or precis)
  + Measurement method (e.g. EORTC QLQ-C30; total score and physical functioning and symptoms subscales), information required to interpret the measure (scale range and direction, minimally important difference) and timing of outcome measurement (exact timing; described in relation to timing of reflexology (e.g. immediately after end of reflexology intervention period) and other treatment (4, 8 and 12 hrs post-surgery)
  + Results including: summary statistics by group (means and standard deviations, or number of events for cognitive outcomes that have been dichotomised, and sample size), estimates of intervention effect (e.g. mean differences (or adjusted mean differences), confidence intervals, t-values, p-values, or risk ratios/odds ratios for binary outcomes).
  + Data required to support risk of bias judgements (see Assessment of risk of bias of included studies) [4]

### B1.1 Assessment of risk of bias of included studies

#### B1.1.1 Assessment of risk of bias in RCTs

We assessed the risk of bias in included studies using the revised Cochrane ‘Risk of Bias’ tool (RoB 2) for randomised trials [4, 19] for each outcome included in the synthesis. For cross-over trials, we used the variant of the RoB 2 tool specific for the design [20]. We planned to use the cluster trial RoB 2 tool for cluster trials and studies in which clustering effects were likely (e.g. those where our assessment was based on the effect of assignment to the intervention); however, no such studies were included.

RoB 2 addresses five domains:

* bias arising from the randomisation process;
* bias due to deviations from intended interventions;
* bias due to missing outcome data;
* bias in measurement of the outcome;
* bias in selection of the reported result.

We applied review-specific guidance developed for the suite of natural therapies reviews to ensure consistency across reviewers. This guidance had been used by the author team to assess over 200 natural therapies studies prior to application in the current review. One review author (KJ, PN, LK, MM) then applied the tool to the selected results from each study following the RoB 2 guidance [20], and a second author (SB) checked a subset of assessments. Advice was sought from the lead reviewer (SB) where there was uncertainty, and the review biostatistician (JM) for more complex scenarios. Supporting information and justifications for judgements for each domain (low, some concerns, high risk of bias) were recorded. We derived an overall summary of the risk of bias from each assessment, following the algorithm in the RoB 2 guidance as implemented in the Excel assessment tool [20].

When multiple effects of the intervention using different approaches were presented in the trial report, we selected one effect for inclusion in the meta-analysis and for risk of bias assessment. The selected effect was chosen according to the following hierarchy, which orders the approaches from (likely) least to most biased for estimating the *effect of assignment to the intervention*: 1. the effect that corresponds to a full intention-to-treat analysis, where missing data have been multiply imputed, or a model-based approach has been used (e.g. likelihood-based analysis, inverse-probability weighting); 2. the effect corresponding to an analysis that adheres to intention-to-treat principles except that the missing outcome data are excluded; 3. the effect that corresponds to a full intention-to-treat analysis, where missing data have been imputed using methods that treat the imputed data as if they were observed (e.g. last observation carried forward, mean imputation, regression imputation, stochastic imputation); or 4. the effect that corresponds to an 'as-treated' or 'per-protocol' analysis, or an analysis from which eligible trial participants were excluded [4, 20]. The effect used in the assessment was recorded in the data extraction form.

### B1.2 Measures of treatment effect

We anticipated that many of the outcomes would be continuous (e.g. pain, anxiety), and that varying measurement instruments would be used to measure the same underlying construct across the studies. For this reason, we quantified the effects of reflexology using the standardised mean difference (SMD) (implementing the Hedges’ adjusted *g* version). In trials where a continuous measure had been dichotomised (e.g. a continuous pain scale is dichotomised into improvement or no improvement) and analysed as binary outcomes, we re-expressed reported, or calculated, odds ratios as SMDs [21]. We did not report any of our meta-analysis results as dichotomous outcomes.

#### B1.2.1 Interpretation of treatment effects

Given the wide range of conditions, outcomes and measurement methods reported in the studies included in this review, it was not possible to specify thresholds for interpreting the size of the effect for each outcome measure. We planned to use Cohen’s guiding rules for interpreting SMDs where 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect [22]. In practice, our interpretation was based on whether there was an important effect or not [23-25], with an SMD of 0.2 standard units set as the threshold for an important difference. If the SMD fell within the pre-specified range of -0.2 to 0.2 (i.e. within both thresholds), the effect of reflexology was considered to be no different from control. An SMD above 0.2 or below -0.2 was interpreted as an important effect. We opted to use the most intuitive interpretation of effect estimates for each outcome, so positive values indicate benefit for some outcomes (an increase in sleep quality, health-related quality of life, and physical function) and harm for other outcomes (an increase in pain, emotional functioning and mental health outcomes such as anxiety or depression, fatigue, and global symptoms). Because we were concerned that bias may be leading to exaggerated effect sizes, we chose not to describe the size of effect (i.e. we did not interpret effects as small, moderate or large).

### B1.3 Unit of analysis issues

In this review, unit of analysis issues arose from non-standard designs (cross-over trials) and from trials with more than two eligible intervention groups (arms). We did not find any eligible cluster trials. In the following we outline the methods that were used for making adjustments when necessary. Any adjustments were indicated on the forest plots and documented. Studies for which we were unable to make the necessary adjustments due to missing information are listed in Appendix E4.

For cross-over trials where an appropriate paired analysis was not available, we attempted to approximate a paired analysis by imputing missing statistics (e.g. correlation). Estimates of the missing statistics were imputed from other cross-over trials included in the review, where possible, or by using external estimates from empirical research (e.g. Balk 2012 [26]).

For trials where more than one comparison from the same trial is eligible for inclusion in the same meta-analysis (e.g. two different doses of reflexology, multiple inactive control groups), we combined intervention groups, where it made sense to do so; otherwise, we reduced the sample size so that the same participants did not contribute more than once (studies with more than one intervention or control group are identified in Appendix E1).

### B1.4 Dealing with missing data

As planned in the protocol, we did not contact trial authors to obtain missing information (e.g. study characteristics, description of conduct of the trial) or aggregate level statistics (e.g. missing standard deviations). However, we attempted to calculate statistics necessary for meta-analysis using algebraic manipulation of reported statistics (e.g. computing the standard error for the treatment effect from a reported p-value). When standard deviations could not be calculated from available statistics, but interquartile ranges or ranges were reported, we used the formula in Wan et al [27] to estimate approximate standard deviations. When neither of the above methods were possible, we imputed the standard deviation using the average standard deviation across trials included in the same meta-analysis that used the same measurement tool in a similar population. When means were missing, but medians are reported, we used the formula in Wan et al [27] to estimate approximate means. Studies for which we calculated or imputed statistics are annotated in forest plots, and the impact of these decisions was explored in sensitivity analyses (see B2.4 sensitivity analyses and Appendix D for results). Studies for which we could not calculate or impute the statistics required for inclusion in the meta-analysis, are listed in Appendix E4 with reasons for why the results could not be included. Appendix E4 also lists studies or results that were either not reported or not useable (e.g. due to errors).

We planned to deal with missing outcome data within the primary trials through sensitivity analyses, where trials judged to be at a high risk of bias or some concerns would be excluded; however, this was not possible because none of the trials included in the review were at low risk of bias (see B2 Data synthesis)[[1]](#footnote-2). Risk of bias ‘due to missing outcome data’ was considered within the overall bias judgement for each trial.

### B1.5 Assessment of heterogeneity

We assessed statistical heterogeneity of the intervention effects visually by inspecting the overlap of confidence intervals on the forest plots, through formal tests for heterogeneity using the χ 2 test (using a significance level of α=0.1), and quantified heterogeneity using the I2 statistic [28]. When there was evidence of heterogeneity, we judged its importance by considering where the point estimates for studies lay in relation to the threshold for an important difference (all on one side, indicating similar interpretations across the studies, or not).

### B1.6 Assessment of biases due to missing results

We planned to use a framework for assessing risk of bias due to missing results in which an assessment is made for each meta-analysis regarding the risk and potential impact of missing results from studies in which we knew an outcome was measured but not reported (termed ‘known-unknowns’) and the risk of other missing studies or results (termed ‘unknown-unknowns’) [28, 29]. The assessment of ‘known unknowns’ involves assessment of whether trials meeting the inclusion criteria for a particular meta-analysis have missing results through examination of the publication’s methods section, trial registry entry (if available), and trial protocol (if available). In practice, the assessment of ‘known unknowns’ was unfeasible due to the large number of included studies and additional studies in trial registers. This assessment was therefore limited to examining the potential impact of studies for which data could not be included in the meta-analysis and those in languages other than English that were judged as being likely to meet the eligibility criteria for each synthesis (see A1.1.1 Types of studies; A3.1 Selection of studies). For the former, we made an assessment as to whether the missing result was potentially due the result itself (e.g. ‘not statistically significant’), and whether inclusion of the result could lead to a notable change in the meta-analysis (e.g. if the missing result is from a large trial). We also considered whether there was evidence of selective non-reporting of results from the assessment of ‘unknown unknowns’ which would mean the synthesis result would already be downgraded for publication bias.

In assessing ‘unknown unknowns’, we judged whether the trials not identified were likely to have results eligible for inclusion (i.e. for the outcome domain ‘pain’, is it likely that missing studies would have been eligible for inclusion in the overall analysis or for particular conditions). We used contour enhanced funnel plots to examine whether there was evidence of small study effects [30]. We also undertook sensitivity analyses to compare the combined effect estimated from the random-effects model (primary analysis) with that estimated from a fixed (common) effect model. If there was compelling evidence of funnel plot asymmetry, with no explanation for the difference (e.g. differences in populations or intensity of the delivery of intervention between small and large trials, differences in risk of bias between small and large trials), then we downgraded for ‘suspected’ reporting (publication) bias. If the random-effects estimate was importantly larger than the fixed-effect estimate, this provided additional evidence that reporting bias was likely.

## B2 Data synthesis

### B2.1 Meta-analysis

Separate comparisons were set up based on outcome domains agreed in the final framework (see Figure A6.1 Appendix A6). These comparisons were stratified by the population groups in the final framework. This approach to structuring the meta-analysis yielded an overall estimate of the effect of reflexology for the outcome (review objective 1), as well as estimates for each population group (review objective 2). Subgroup analysis by population group was used to examine whether these population groups explained any observed statistical heterogeneity in the intervention effects (see Subgroup analysis).

We combined the effects using a random effects meta-analysis model, since we expected and found there to be clinical and methodological diversity across the trials that may contribute to statistical heterogeneity. These analyses used the restricted maximum likelihood estimator (REML) of between trial heterogeneity variance and the Hartung-Knapp-Sidik-Jonkman confidence interval method. Analyses were conducted in Stata Statistical Software [31].

Forest plots were used to visually depict the intervention effect estimates and their confidence intervals. Forest plots are stratified by condition and risk of bias (within population group).

### B2.2 Summary and synthesis when meta-analysis is not possible

Studies that were eligible for the evidence synthesis but could not be included in meta-analyses, are included in the characteristics of included studies table (Appendix E1). These studies are counted as ‘missing results’ rather than included in a summary or other synthesis (i.e. the result was judged to be uninterpretable or there were major concerns about the integrity of the data). Details of the syntheses for which each of the studies was eligible are tabulated, together with the reason why data are missing (Appendix E4). We do not report the results from these studies (if available) because of concerns about the validity of the data and because the individual studies are unlikely to change the findings from the meta-analyses (i.e. we were able to include the majority of studies in meta-analyses). Nor did we assess risk of bias because bias (under- or over-estimating the effect) is only relevant if results are included in a meta-analysis or reported. The reasons why these studies were not included in the analysis do not relate to bias (i.e. incomplete reporting of effects and their variances, errors in reporting or analysis of data, no information to interpret), so a risk of bias assessment would not characterise the problems with these studies.

### B2.3 Subgroup analysis and investigation of heterogeneity

We undertook a subgroup analysis to examine whether population group explains any observed statistical heterogeneity in the intervention effects, using the pre-defined groups specified in the final framework (see Figure A6.1 for population groups in each meta-analysis). Results for these analyse are presented in the forest plots in the main results, considered in the GRADE judgements on inconsistency, and described in more detail in Appendix D.

### B2.4 Sensitivity analyses

We undertook and report sensitivity analyses examining if the meta-analysis estimates were robust to the:

* *meta-analysis model*. In addition to fitting a random-effects model, we fitted fixed effect models. The analysis was undertaken to investigate the impact of any small-study effects.
* *assumptions made to enable inclusion of results in the meta-analysis,* specifically transforming or imputing statistics, and including change scores (change from baseline) when post-intervention (final) values (and their standard deviations) were unavailable.

Results of the sensitivity analyses were tabulated, including the meta-analysis estimate (and its confidence interval), along with details of the original and sensitivity analysis assumptions (Appendix D).

We also planned to undertake sensitivity analyses examining if the meta-analysis estimates were robust to inclusion of trials judged to be at an overall high risk of bias or some concern. We planned to exclude trials judged to be at an overall high risk of bias or some concerns; however, there were no trials judged to be at low risk of bias in the review, so these sensitivity analyses could not be performed.

In addition to our planned sensitivity analyses, the senior biostatistician on the review (JM) undertook checks of a sample of studies reporting extremely large effects (SMD >3.0) to attempt to verify the data by matching the statistics reported by the trialists. For example, by calculating the standard deviation (SD) of change from results from a paired t-tests, it was possible to examine the correlation between the SD of change and the reported SDs. A correlation that falls outside the range of a correlation (i.e. between -1 and 1), indicates an issue with the reported standard deviations. In the absence of being able to verify the data reported by the trialists, we took a precautionary approach and excluded the results from the analysis. All studies excluded on this basis are reported in Appendix E4.

### B2.5 Summary of findings tables and assessment of certainty of the body of evidence

We prepared GRADE summary of findings tables for each of the main comparisons, reporting results for critical and important outcome domains (up to seven). For each result, one author (SB) used the GRADE approach to assess our confidence in where the effect lies relative to our threshold for a small effect (the certainty of evidence) (see Measures of treatment effect). In accordance with detailed GRADE guidance [22, 25, 32], an overall GRADE of high, moderate, low or very low certainty is reported for each result based on whether there are serious, very serious or no concerns in relation to each of the following domains [23].

1. **Risk of bias**. We assessed the overall risk of bias across all studies contributing to each synthesised result. All studies were rated at high risk of bias or some concerns (i.e. contributed 100% of the weight in all meta-analyses). As such, it was not possible to perform sensitivity analyses to examine whether removing studies at high risk of bias or some concerns changed the direction or size of effect estimate importantly (a reduction in benefit or an increase in harm being most concerning) (see Sensitivity analyses). We therefore rated down all results for risk of bias. Where the majority of studies were at high risk of bias, we rated down for very serious concerns, especially if effects were large (given concerns about bias due to selection of the reported result) or borderline (such that bias may shift the estimate from trivial to important).
2. **Imprecision**. We judged imprecision by examining where the 95% confidence interval for each pooled effect estimate lay in relation to our threshold for an important effect (an SMD of -0.2 or 0.2; see Measures of treatment effect). Where the confidence interval crossed a threshold leading to different interpretations (e.g. interpretation of the upper bound of the interval was ‘an important effect’ and the lower bound ‘little or no effect’), we considered rating down for imprecision. If the extent to which the confidence interval crossed the threshold was modest, and the interpretation was consistent with the point estimate, we did not rate down (e.g. if the upper bound of the confidence interval was an SMD of -0.15 and the point estimate -0.50). We rated down for serious imprecision if the confidence interval crossed one threshold (important benefit or important harm) and the interpretation of either the upper or lower bound of the interval was different from the point estimate (e.g. if the upper bound of the confidence interval was an SMD of 0.40 indicating an important increase in pain, and the point estimate was -0.15 indicating an unimportant reduction in pain). We rated down for very serious imprecision if the confidence interval crossed two thresholds (important benefit and important harm) and for extremely serious imprecision where the confidence interval was so wide that the result was considered uninterpretable. In line with GRADE guidance, we considered the likely impact of inconsistency when rating imprecision since inconsistency can contribute to imprecision [33, 34].
3. **Inconsistency**. We assessed whether there was important, unexplained inconsistency in results across studies considering the overlap of confidence intervals (non-overlap indicating potentially important differences in direction or size of effect), statistical measures that quantify and test for heterogeneity (I2 statistic, χ2 test), and where the point estimates lie in relation to the threshold for an important effect (if all to one side of a threshold, we were less concerned). To enhance our interpretation of whether inconsistency is important, we also examined the prediction interval, considering whether it included values that lead to a different conclusion than an assessment based on the confidence interval [35]. Where there was evidence of importantly inconsistent results, we considered whether the results of subgroup analyses provided a credible explanation for the inconsistency (see Assessment of heterogeneity; specifically, the population subgroups. Where inconsistency was not explained, we rated down. Where a result was based on a single study, inconsistency was not rated [33].
4. **Indirectness.** We assessed whether there are important differences between the characteristics of studies included in each synthesis and the question we were seeking to address, such that the effects observed may not apply to our question (i.e. the applicability of the evidence). For example, differences between the interventions delivered and reflexology practice in Australia that are likely to influence the size of effect. Where results came from a single small study, we were concerned that similar effects might not be observed in the population of interest more generally, and rated down for serious indirectness. Where the included studies addressed only part of the population of interest (e.g. the only form of acute pain was dysmenorrhea), we did not rate down for indirectness. Instead, we specified the population from which data came when interpreting results and indicated uncertainty for the population group more generally.
5. **Publication bias**. Our judgement of publication bias was based on assessment of bias due to missing results, primarily from interpretation of contour enhanced funnel plots (see Assessment of biases due to missing results). In these assessments, we also considered the potential impact of excluding studies in languages other than English and of data that could not be included in the meta-analyses.
6. **Upgrading domains** (large effect size, dose response gradient, opposing plausible residual confounding). While, in principle, these domains apply to randomised trials, there is no precedent for rating up the evidence from randomised trials, and we did not have reason to apply them in this review.

Using GRADE decision rules, we derived a GRADE for the certainty of evidence for each result included in the summary of findings table [32]. evidence (score=4), and can be rated down (-1 A result from a body of evidence comprised of randomised trials begins as ‘high’ certainty or -2) for serious or very concerns on any GRADE domain that reduces confidence that reflexology has an important effect (as determined by the pre-specified thresholds) [32, 36, 37]. As indicated in point 2, we applied the most recent GRADE guidance which has provision for rating down (-3) for extremely serious imprecision.

Summary of findings tables were prepared using the GRADEpro GDT software. The tables include:

* estimates of the effects of reflexology reported as standardised mean differences
* the overall GRADE (rating of certainty) and an explanation of the reason(s) for rating down (or borderline decisions) [38].
* the study design(s), number of studies and number of participants contributing data
* a plain language statement interpreting the evidence for each comparison and outcome, following GRADE guidance for writing informative statements (see B2.6 interpretation of findings) [24].

We present the certainty of evidence in summary of findings tables using one of four levels with the following symbols and interpretations.

|  |  |  |
| --- | --- | --- |
| **Certainty** | **GRADE interpretation** | **Implications** |
| High (⊕⊕⊕⊕) | we are very confident that the true effect lies close to that of the estimate of the effect | further research is very unlikely to change the confidence in the estimate of effect |
| Moderate (⊕⊕⊕⊝) | we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. | further research is likely to have an important impact in the confidence in the estimate of effect |
| Low (⊕⊕⊝⊝) | our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. | further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate |
| Very low (⊕⊝⊝⊝) | we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | any estimate of effect is very uncertain |

### B2.6 Interpretation of findings (evidence statements)

When interpreting results, we followed GRADE guidance for writing informative statements [24]. All interpretations are based on where the point estimate lies in relation to the pre-specified thresholds for an important effect (an important effect or not) and the direction of effect (beneficial or harmful). The certainty of evidence is communicated by qualifying the interpretation of effect (e.g. ‘probably’ improves for moderate certainty). For low certainty evidence the interpretation is qualified with the word ‘may’. For example, ‘Reflexology may improve sleep quality’ indicates that the point estimate lies above the threshold for important benefit (an SMD >0.2) and that the evidence is of low certainty.

For very low certainty evidence, we do not provide an interpretation of the result except to state ‘The evidence is very uncertain about the effect of reflexology on outcome’. This is one of two options that GRADE provides for interpreting findings based on very low certainty of evidence: “one option gives the direction of the effect, the other does not” [24]. The decision not to interpret very low certainty results was made independently by the NTWC to ensure a consistent and clear interpretation of findings across Natural Therapy Review reports (see Appendix G).

# References for Appendix A and B

1. National Health and Medical Research Council: **Statement of requirement: Evidence evaluations for review of natural therapies (tranche two).** 2020.

2. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR: **A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery.** *Journal of Clinical Epidemiology* 2018, **96:**84-92.

3. World Health Organisation: **International statistical classification of diseases and related health problems (11th ed.) Available from:** [**https://www.who.int/classifications/classification-of-diseases**](https://www.who.int/classifications/classification-of-diseases) **Access date: 15 January 2021** 2019.

4. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al: **RoB 2: a revised tool for assessing risk of bias in randomised trials.** *BMJ* 2019, **366:**l4898.

5. Steel A: **PRACI Study: unpublished data.** 2021.

6. Steel A, Leach M, Wardle J, Sibbritt D, Schloss J, Diezel H, Adams J: **The Australian Complementary Medicine Workforce: A Profile of 1,306 Practitioners from the PRACI Study.** *J Altern Complement Med* 2018, **24:**385-394.

7. McKenzie JE, Brennan SE, Ryan RE, Thomson HJ, Johnson RV, Thomas J: **Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis.** In *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd edition. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Welch V. Chichester (UK): John Wiley & Sons; 2019

8. **The Reflexology Association of Australia. Definition. Available from:** [**https://www.reflexology.org.au/**](https://www.reflexology.org.au/) **Access date: 03 Feb 2022** [<https://www.reflexology.org.au/>]

9. National Health and Medical Research Council: **Reflexology description developed in conversation with the National Health and Medical Research Council’s Natural Therapies Working Committee Chair and the Department of Health’s Natural Therapies Review Expert Advisory Panel (February 2020).** 2020.

10. **How CENTRAL is created. Available from:** [**https://www.cochranelibrary.com/central/central-creation**](https://www.cochranelibrary.com/central/central-creation) **Access date: 7 February 2021**

11. Horsley T, Dingwall O, Sampson M: **Checking reference lists to find additional studies for systematic reviews.** *Cochrane Database Syst Rev* 2011**:**MR000026.

12. Briscoe S, Bethel A, Rogers M: **Conduct and reporting of citation searching in Cochrane systematic reviews: A cross-sectional study.** *Res Synth Methods* 2020, **11:**169-180.

13. Wright K, Golder S, Rodriguez-Lopez R: **Citation searching: a systematic review case study of multiple risk behaviour interventions.** *BMC Med Res Methodol* 2014, **14:**73.

14. Cooper C, Booth A, Britten N, Garside R: **A comparison of results of empirical studies of supplementary search techniques and recommendations in review methodology handbooks: a methodological review.** *Syst Rev* 2017, **6:**234.

15. National Health and Medical Research Council: **Draft framework for protocols for systematic reviews of randomised controlled trials and non-randomised studies of interventions.** 2020.

16. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN: **The REDCap consortium: Building an international community of software platform partners.** *J Biomed Inform* 2019, **95:**103208.

17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: **Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support.** *J Biomed Inform* 2009, **42:**377-381.

18. Hoffmann T, Glasziou P, Barbour V, Macdonald H: **Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide.** *BMJ* 2014, **1687:**1 - 13.

19. Higgins JPT, Savovic J, Page MJ, Sterne JAC: **Revised Cochrane risk-of-bias tool for randomized trials (RoB 2). Available from** [**https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2**](https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2)**. Access date: 8 February 2021.** 2019.

20. Higgins JPT, Eldridge SM, Li T: **Chapter 23: Including variants on randomized trials. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane. Available from** [**www.training.cochrane.org/handbook**](../www.training.cochrane.org/handbook)**.** (Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V eds.); 2020.

21. Chinn S: **A simple method for converting an odds ratio to effect size for use in meta-analysis.** *Stat Med* 2000, **19:**3127-3131.

22. Schünemann HJ, Vist GE, Higgins J, Santesso N, Deeks JJ, Glasziou P, Akl EA, Guyatt GH, On behalf of the Cochrane GRADEing Methods Group: **Chapter 15: Interpreting results and drawing conclusions.** In *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd edition. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Welch V. Chichester (UK): John Wiley & Sons; 2019

23. Brennan SE, Johnston RV: **Research Note: Interpreting findings of a systematic review using GRADE methods.** *Journal of Physiotherapy* 2023.

24. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, Brignardello-Petersen R, Carrasco-Labra A, De Beer H, Hultcrantz M, et al: **GRADE guidelines: 26. informative statements to communicate the findings of systematic reviews of interventions.** *Journal of Clinical Epidemiology* 2019.

25. Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G, Izcovich A, Sadeghirad B, Alexander PE, Devji T, et al: **GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings.** *J Clin Epidemiol* 2021, **137:**163-175.

26. Balk EM, Earley A, Patel K, Trikalinos TA, Dahabreh IJ: **Empirical Assessment of Within-Arm Correlation Imputation in Trials of Continuous Outcomes. Methods Research Report. (Prepared by the Tufts Evidence-based Practice Center under Contract No. 290-2007-10055-I.) AHRQ Publication No. 12(13)-EHC141-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2012.** [**www.effectivehealthcare.ahrq.gov/reports/final.cfm**](../www.effectivehealthcare.ahrq.gov/reports/final.cfm)**.** In; 2012: *AHRQ Methods for Effective Health Care*].

27. Wan X, Wang W, Liu J, Tong T: **Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.** *BMC Med Res Methodol* 2014, **14:**135.

28. Higgins JP, Thompson SG: **Quantifying heterogeneity in a meta-analysis.** *Stat Med* 2002, **21:**1539-1558.

29. Page MJ, Higgins JPT, Sterne JA: **Chapter 13: Assessing risk of bias due to missing results in a synthesis. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane. Available from** [**www.training.cochrane.org/handbook**](../www.training.cochrane.org/handbook)**.** (Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V eds.); 2020.

30. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L: **Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.** *J Clin Epidemiol* 2008, **61:**991-996.

31. StataCorp: **Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC.** 2021.

32. Schünemann HJ, Higgins J, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH, On behalf of the Cochrane GRADEing Methods Group (formerly Applicability and Recommendations Methods Group) and the Cochrane Statistical Methods Group: **Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence.** In *Cochrane Handbook for Systematic Reviews of Interventions.* 2nd edition. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Welch V. Chichester (UK): John Wiley & Sons; 2019

33. Guyatt G, Zhao Y, Mayer M, Briel M, Mustafa R, Izcovich A, Hultcrantz M, Iorio A, Alba AC, Foroutan F, et al: **GRADE Guidance 36: Updates to GRADE's approach to addressing inconsistency.** *J Clin Epidemiol* 2023.

34. Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, Traversy G, Akl EA, Mayer M, Schunemann HJ, Guyatt GH: **GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach.** *J Clin Epidemiol* 2022, **150:**216-224.

35. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G: **CINeMA: An approach for assessing confidence in the results of a network meta-analysis.** *PLoS Med* 2020, **17:**e1003082.

36. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, et al: **The GRADE Working Group clarifies the construct of certainty of evidence.** *Journal of Clinical Epidemiology* 2017.

37. Schunemann HJ, Brozek J, Guyatt G, Oxman AD (Eds.): **Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach**. Hamilton, Canada: McMaster University; 2013.

38. Santesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P, Lasserson T, Opiyo N, Kunnamo I, Sinclair D, et al: **Improving GRADE Evidence Tables part 3: Guidance for useful GRADE certainty in the evidence judgments through explanatory footnotes.** *J Clin Epidemiol* 2016.

# Appendix C. Lists of studies considered for review

## Overview of Appendix C – separate file

Appendix C is comprised of four parts (below).

These Appendices report the studies excluded at full text review with reason for exclusion, the public submissions and eligibility decision for each, the studies awaiting classification (including studies in languages other than English), and the studies included on the evidence inventory.

|  |
| --- |
| Appendix C1. Citation details of studies from search results excluded |
| Appendix C2. Citation details of studies from public submissions |
| Appendix C3. Citation details of studies for studies on the evidence inventory |
| Appendix C4. Citation details of studies awaiting classification |
| Appendix C5. Citation details of ongoing studies\* |

# Appendix D. Extended results and citations for studies included in the evidence synthesis

## Overview of Appendix D – separate file

Appendix D is comprised of a single file in which we report results for additional subgroup analyses, sensitivity analyses and analyses to inform the assessment of biases due to missing results from each synthesis.

The Appendix begins with a brief statement about where information about the characteristics of included studies and risk of bias assessments are located. It is then ordered by outcome as per the results section in the main report.

Appendix D also contains the reference list for studies included in the evidence synthesis.

Sections are as follows

|  |
| --- |
| D1 Pain |
| D2 Sleep |
| D3 Fatigue |
| D4 Emotional functioning and mental health |
| D5 Health-related quality of life |
| D6 Physical function |
| D7 Global symptoms |
| D8 Citation details of studies included in the evidence synthesis |

# Appendix E. Characteristics of studies included in the review

## Overview of Appendix E – separate files

Appendix E is comprised of four parts, each in a separate file.

**Appendix E1** provides information about the characteristics of each of the studies eligible for the evidence synthesis.

* study ID, location, setting, and study design
* the population eligibility criteria, number of participants randomised, participant characteristics, and ICD-11 codes
* the reflexology treatment goal, and details about the reflexology intervention(s) and comparator(s)
* a list of all reported outcome(s) categorised according to whether they were eligible or ineligible for the synthesis, the measurement method for each eligible outcome, the timing of outcome measurement, and the outcome(s) selected for inclusion in the synthesis for each outcome domain

**Appendix E2** provides information about funding, declaration of interest and ethics approval for each study.

Studies were included in E1 and E2 irrespective of whether they provided data that could be included in the meta-analysis.

**Appendix E3** provides details of the characteristics of each of the studies included in the evidence inventory. These studies were either studies specified to be included in the inventory as per the protocol (studies versus active comparators which were not gold standard, no eligible outcomes), or eligible for the review, but were excluded from the synthesis because the criteria for synthesis were not met (at least two studies at low risk of bias addressing a similar PICO). The reasons why each study was excluded from the synthesis is reported in this file.

**Appendix E4** provides a list of studies that were eligible for the evidence synthesis, but for which data could not be included in the meta-analysis. Details of the syntheses for which each of the studies was eligible are tabulated, together with the number of participants and the reason why data are missing.

Appendices are as follows

|  |
| --- |
| E1. Characteristics of studies included in the evidence synthesis |
| E2. Funding sources, potential conflicts of interest and ethics approval for studies included in the evidence synthesis |
| E3. Characteristics of studies included in the evidence inventory (ineligible for the evidence synthesis) |
| E4. List of studies eligible for the evidence synthesis with data that could not be included for meta-analysis |

# Appendix F. Risk of bias assessments

## Overview of Appendix F – separate file

Appendix F is a single file containing the full risk of bias assessment for each study that contributed data for meta-analysis.

The Appendix

* begins with information to orient the reader to the content,
* provides the signalling questions for the risk of bias tools, and
* includes additional methods information about how trials with clustering were handled.

# Appendix G. Differences between the protocol and the review

Changes from the protocol and methods not implemented

|  | Section | Planned method | Change | Details (text, rationale or both) |
| --- | --- | --- | --- | --- |
| 1 | A1.1.3 | We planned to examine the effects of reflexology compared to “gold standard” (evidence-based) treatments, in the exceptional circumstance that there were studies at low risk of bias that could be combined in a synthesis (i.e. similar enough PICO). | Active comparators were not included in synthesis | Agreement was reached that the planned comparison of the effects of reflexology compared to evidence-based treatments was not feasible because of the large volume of evidence contributing to objectives 1 and 2.  Subsequent inspection of the trials with an active comparator showed that the criteria for synthesis were not met. Studies that only reported an active comparison are reported on the evidence inventory (E3). Studies that reported both an inactive comparison (i.e. eligible for the synthesis) and an active comparison are in the characteristics of included studies table (E1).  We had 50 studies reporting 43 active comparators (note, some were from studies in the synthesis that also reported an inactive comparison)  16 of 43 were ineligible comparators (head-to-head comparisons of reflexology or another of natural therapy [mainly aromatherapy],  13 of 43 were potentially evidence-based treatments (a drug, physiotherapy),  2 of the 13 were considered in more than 1 study (2 studies of guided imagery; 2 of support during labor)  All four studies were at high risk of bias or some concerns |
| 2 | A2.2 Searching other resources | Where these groups [making submissions] recommend particular systematic reviews, we will examine references for included studies to identify potentially eligible randomised trials. | We did not screen the reference lists of reviews | **Text deleted.**  **Rationale**. Our search was comprehensive, limited to randomised trials (which are unlikely to be missed using the search methods employed for this review), and the findings of the review are unlikely to change with the addition of additional trials. |
| 3 | A3.1 Selection of studies | The following will be included in a list of ‘studies awaiting classification’:  Studies that are only published as abstracts or for which a full report is not available (i.e. we will not seek further information from study authors to confirm eligibility).  Studies confirmed as likely to be eligible, but for which no English language translation of the full-text publication is available.  Studies for which eligibility cannot be confirmed following translation of the title and abstract using Google translate. | Additional code for studies awaiting classification | **Text added**. “Studies for which a full report was available but the report was incomplete or ambiguous such that eligibility based on one or more PICO criteria or study design could not be confirmed (i.e. we did not seek further information from study authors to confirm eligibility)” |
| 4 | A3.1 Selection of studies | Studies that did not meet the eligibility criteria were excluded and the reason for exclusion was recorded at full-text screening. These studies are included in a ‘Characteristics of excluded studies’ table in which the reason for exclusion is reported. | Additional check of eligibility at data extraction | **Revised text**. “Studies that did not meet the eligibility criteria were excluded and the reason for exclusion was recorded at full-text screening. *Inclusion decisions were checked at data extraction, and for any studies identified as ineligible at this stage, the decision and exclusion reason were recorded in Covidence.* These studies are included in a ‘Characteristics of excluded studies’ table in which the reason for exclusion is reported.” |
| 5 | A3.1 Selection of studies | For studies that originated from the call for evidence, we will record and report exclusion decisions irrespective of whether the study was excluded during title and abstract screening or full text review. We will document the flow of these studies through the review in the PRISMA flow chart and annotate tables with the source. | We did not annotate tables with source because no additional studies were identified | **Revised text**. “For studies that originated from the call for evidence we recorded and reported exclusion decisions irrespective of whether the study was excluded during title and abstract screening or full text review. We documented the flow of these studies through the review in the PRISMA flow chart and in Appendix C2.” |
| 6 | A3.1 Selection of studies | Records were to be matched using trial registry numbers. Where these were not available, we considered author names, trial name, trial location(s) and number of participants. | Additional information was required to match multiple trial records | **Revised text**. “Records were matched using trial registry numbers. Where these were not available, we considered author names, trial name, trial location(s), number of participants, *baseline characteristics and PICO*.” |
| 7 | A3.1 Selection of studies | We planned to screen all registry records to identify ongoing studies and to conduct an analysis of missing results. | Screening limited to that required to match records to included studies | **Revised text**. The trial register records retrieved from CENTRAL (i.e. from ClinicalTrials.gov and WHO ICTRP) were used to identify matching records for included studies. We did not screen the unmatched records (428) to ascertain the likely number of potentially eligible trials for which there was no full text report (i.e. missing or ongoing studies). It was not feasible to perform the more detailed analyses required to determine which meta-analysis each ongoing or missing trial would contribute (i.e. examination of the PICO questions addressed in each study and matching to meta-analysis PICOs). As such, we followed the decision previously made in consultation with NHMRC for another large natural therapies review not to screen the trial register records or the full registry entry given the volume of studies eligible for the review and that an analysis of registry records would contribute little additional information. |
| 8 | A3.1 Selection of studies | Standard one-step process for screening full text studies was planned. | An additional check of study eligibility was added at data extraction | **Revised text.** Inclusion decisions were checked at data extraction, and for any studies identified as ineligible at this stage, the decision and exclusion reason were recorded in Covidence.  **Rationale**. Some studies required more detailed review (often across multiple reports) to confirm eligibility. |
| 9 | B1.2 Measure of treatment effect | Where a valid and reliable minimal important difference (MID) is available for a familiar measure of relevance to the population groups in the meta-analysis, we will re-express the SMD in units of the measure and interpret the effect in relation to the MID if feasible to do so. | We did not re-express SMDs in units of a familiar measure | **Rationale**. Due to the diversity of populations, population-specific outcomes, and outcome measures, it was not feasible to re-express the SMDs using a familiar measure. |
| 10 | B1.2 Measure of treatment effect | For dichotomous outcomes, we will seek advice from NTWC on interpreting the size of the effect (seeking agreement on a threshold for a small but important difference). | Method not required. | **Rationale.** We did not report dichotomous analyses for any of our meta-analyses. For most of our analyses, all included studies reported continuous outcomes. For some analyses (e.g. pain) the majority of outcomes were continuous but some were dichotomous having been dichotomised from a continuous measure. We re-expressed these results using the SMD, hence there was no need to interpret dichotomous outcomes. |
| 11 | B1.2 Measure of treatment effects | We planned to use Cohen’s guiding rules for SMDs where 0.2 represents a small effect, 0.5 a moderate effect, and 0.8 a large effect. | We used a single threshold for an important effect (0.2) and did not interpret effect size. | **Revised text (and rationale).** Because we were concerned that bias may be leading to exaggerated effect sizes, we chose not to describe the size of effect (i.e. we did not interpret effects as small, moderate or large) because this is likely to be misleading.  **Implications.** This has no implications for the certainty of evidence because our a priori plan was to assess certainty in relation to whether there was an important effect or not (i.e. in relation to a threshold for an important difference of an SMD of 0.2), not our certainty in the magnitude of effect (trivial, small, moderate or large). |
| 12 | B1.6 Assessment of bias due to missing results | We planned to undertake a full assessment of ‘known-unknowns’ to determine whether results are missing from each meta-analysis, by examining the methods section, trial registry entry (if available), and trial protocol (if available) for trials meeting the inclusion criteria for the meta-analysis. | Assessment not done (with some exceptions) | **Revised text (and rationale)**. “In practice, the assessment of ‘known unknowns’ was infeasible due to the large number of included studies and additional studies in trial registers. This assessment was therefore limited to examining the potential impact of studies for which data could not be included in the meta-analysis and those in languages other than English that were judged as being likely to meet the eligibility criteria for each synthesis.”  **Implications**. Likely to be minimal. We downgraded the certainty of evidence for publication bias for most analyses (overall, some subgroups) based on evidence from contour enhanced funnel plots and sensitivity analyses, so additional downgrades would not apply. |
| 13 | B2.2  Summary and synthesis when meta-analysis is not possible | For a particular comparison, if we are unable to analyse most of the effect estimates (due to incomplete reporting of effects and their variances, variability in the effect measures across the studies), we will consider alternative synthesis methods … | Other synthesis methods not used | **Rationale.** We were able to analyse most of the effect estimates. Concerns about the integrity of data led to a decision not to report results from studies that could not be included.  Text in this section has been revised accordingly. |
| 14 | B2.4 Sensitivity analysis | Analysis to examine the impact of risk of bias. | Could not be done | **Revised text.** All studies were rated at high risk of bias or some concerns (i.e. contributed 100% of the weight in all meta-analyses). As such, it was not possible to perform sensitivity analyses as per the protocol to examine whether removing studies at high risk of bias or some concerns changed the direction or size of effect estimate importantly (a reduction in benefit or an increase in harm being most concerning) |
| 15 | B2.4  Sensitivity analysis | Our stated method was to undertake and report sensitivity analyses in which we excluded “trials judged to be at an overall high or unclear risk of bias.” | Terminology updated (not a change to protocol) | **“**Unclear risk of bias” is the terminology used in the original Cochrane ROB tool and protocol. Updated ROB2 terminology replaces this wording with “some concerns”. |
| 16 | B2.4  Sensitivity analysis | Sensitivity analysis | Additional analysis | We conducted an additional sensitivity analysis, not mentioned in our protocol, to examine if the meta-analysis estimates were robust to “the assumptions made to enable inclusion of results in the meta-analysis, specifically (1) transforming or imputing statistics, and (2) including change scores (change from baseline) when post-intervention (final) values (and their standard deviations) were unavailable.” |
| 17 | B2.5 GRADE assessment - imprecision | For large effects, we planned to consider whether the sample size meets the optimal information size (based on number of events for binary outcomes; sample size for continuous outcomes). | We did not do this. | We did not consider sample size in judging imprecision for large effects, partly because we interpreted effects only in relation to a threshold for a small important effect (thus, whether the effect was slight or large was not factored in) and partly because concerns about large effects in small studies are driven by concerns about publication bias, which we considered. We were concerned that results from single studies, or where the aggregate sample size was small, may not be similar to what would be observed in the population of interest more generally. For this reason, we considered the potential for indirectness in these circumstances. |
| 18 | B2.5 GRADE assessments – risk of bias | As per B2.4 we did not use the term ‘some concerns’ in the protocol when describing our approach to rating down for risk of bias | Terminology updated (not a change to protocol) | The use of ‘some concerns’ is consistent with the use of the ROB2 tool. Our approach to GRADE is consistent with that for sensitivity analyses where downgrades of -1 are considered where the majority of studies are rated as ‘some concerns’ or studies with the majority of weight in the analysis are rated as ‘high risk of bias’. Downgrades of  -2 are made where most or all studies are at high risk of bias. Decisions not to rate down in these circumstances would be warranted if sensitivity analyses showed removal of studies at risk of bias did not materially alter the effect estimate. |
| 19 | B2.6 Interpretation of findings | Our endorsed protocol stated that we would report “a plain language statement interpreting the evidence for each comparison and outcome, following GRADE guidance for writing informative statements”. We did not specify which option would be used for very low certainty evidence (i.e. give the direction of the effect, or limit to a statement that the ‘evidence is very uncertain’). | We did not include direction of effect for very low certainty evidence. | Rationale. To ensure a consistent and clear approach across reviews, the NTWC advised that direction of effect should not be included in evidence statements for very low certainty evidence. The advice was provided after the protocols were endorsed, but prior to any analyses being undertaken. |

# Appendix H. Response to comments from the Methodological review

Methodological review (or peer review) was conducted to appraise the methodological quality and assess the appropriateness of reporting for this systematic review (including appendices).

For reporting, the methodological review assessed the systematic review against the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Checklist (2020) and where applicable, the MECIR (Methodological Expectations of Cochrane Intervention Reviews) manual to ensure the systematic review was designed and conducted in accordance with:

* NHMRC’s Developing your Guideline module in NHMRC’s Guidelines for Guidelines Handbook
* Cochrane Handbook for Systematic Reviews of Interventions (updated 2022)
* GRADE guidance and GRADE working group criteria for determining whether the GRADE approach was used (GRADE handbook).

Assessment included the application of criteria for considering studies for the review and synthesis, search methods, data extraction and analysis, assessment of risk of bias of studies, assessment of the certainty of evidence using GRADE, and the interpretation and summary of findings.

The systematic review (including appendices) has been updated to reflect the amendments suggested by methodological review and NHMRC’s Natural Therapies Working Committee, where appropriate. In summary, updates included additional information and/ or clarification of the Plain Language Summary, Executive Summary, Results sections and Appendices, including:

* Clarification of comparators in various parts of the report
* GRADE judgements clarified and confirmed where appropriate.
* Clarifications to the PRISMA diagram.
* Rewording in various parts of the report for clarity and consistency across reports.

A detailed record of responses to all comments indicating changes that were made was provided to NHMRC together with the amended Report and Appendices documents.

# Appendix I. Abbreviations

Below is a list of abbreviations used in the report. Abbreviations for outcome measures are in a table following the list.

**AMED:** Allied and Complementary Medicine Database

**CENTRAL:** Cochrane Central Register of Controlled Trials

**CINAHL:** Cumulative Index of Nursing and Allied Health Literature

**CM:** Complementary Medicine

**COMET:** Core Outcome Measures in Effectiveness Trials

**DEFF:** design effect

**GRADE:** Grading of Recommendations, Assessment, Development and Evaluation

**ICC:** intra-cluster correlation

**ICD-11:** International Classification of Diseases 11th Revision

**ICTRP:** International Clinical Trials Registry Platform

**MA: Meta-analysis**

**MeSH:** Medical Subject Headings

**MID:** minimal important difference

**NHMRC:** National Health and Medical Research Council

**NRSI:** non-randomised study of interventions

**NTREAP:** Natural Therapies Review Expert Advisory Panel

**NTWC:** Natural Therapies Working Committee

**PICO:** population, intervention, comparator, outcome

**PRACI:** Practitioner Research and Collaboration Initiative

**PRISMA:** Preferred Reporting Items for Systematic review and Meta-Analyses

**PRISMA-P:** Preferred Reporting Items for Systematic review and Meta-Analyses Protocols

**RCT:** randomised controlled trial

**REML:** restricted maximum likelihood estimator

**RR:** risk ratios

**SMD:** standardised mean difference

**TIDieR:** Template for Intervention Description and Replication

**TGA:** Therapeutic Goods Administration

**Abbreviations for measures reported in this review**

|  |  |
| --- | --- |
| AQ20 | Airways Questionnaire 20 |
| AARS | Apparent Affect Rating Scale |
| ACQ | Asthma Control Questionnaire |
| AQLQ | Asthma Quality of Life Questionnaire |
| BAI | Beck Anxiety Inventory |
| BDI | Beck Depression Inventory |
| BFI | Brief Fatigue Inventory |
| BPI | Brief Pain Inventory |
| BPI-SF | Brief Pain Inventory - Short Form |
| BSPAS | Burn Specific Pain Anxiety Scale |
| CHQ-PF50 | Child Health Questionnaire |
| CAS | Constipation Assessment Scale |
| CQLS | Constipation Quality of Life Scale |
| CSI | Constipation Severity Instrument |
| CAT | COPD Assessment Test |
| DASS-21 | Depression Anxiety and Stress Scale 21 |
| EORTC QLQ-C30 | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire |
| EORTC-CIPN-20 | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-induced Peripheral Neuropathy |
| FLACC | Face, Legs, Activity, Cry, Consolability Scale |
| FIS | Fatigue Impact Scale |
| FSS | Fatigue Severity Scale |
| FSC | Fatigue Symptoms Checklist |
| FACT-B scale | Functional Assessment of Cancer Therapy–Breast |
| GPM | Geriatric Pain Measure |
| GMFM | Gross Motor Function Measure |
| HADS | Hospital Anxiety and Depression Scale |
| Holmes & Dickerson | HR-QoL VAS |
| ICS | Infant Colic Scale |
| IRLS | International Restless Legs Scale |
| IRLS | IRLS Restless Legs Syndrome Rating Scale |
| KHQ | King's Health Questionnaire |
| KOOS | Knee injury and Osteoarthritis Outcome Score |
| MDASI | M.D. Anderson Symptom Inventory |
| MPQ | McGill Pain Questionnaire |
| MENQOL | Menopause-specific Quality of Life |
| MCAS | Modified Constipation Assessment Scale |
| MFIS | Modified Fatigue Impact Scale |
| MFI-20 | Multidimensional Fatigue Inventory 20-item |
| MQOLS-CA | Multidimensional Quality-of-Life Scaled Cancer |
| MSIS-29 | Multiple Sclerosis Impact Scale |
| MSQOL-54 | Multiple Sclerosis Quality of Life-54 |
| MSSE | Multiple Sclerosis Self-Efficacy Scale |
| NDI | Neck Disability Index |
| N-PASS | Neonatal Pain, Agitation and Sedation Scale |
| NDS | Neuropathy Disability Score |
| NSS | Neuropathy Symptom Score |
| NPRS | Numeric Pain Rating Scale |
| NRS | Numerical Rating Scale |
| OSBD-R | Observational Scale of Behavioral Distress-Revised |
| ODQ | Oswestry Low Back Pain Disability Questionnaire |
|  | Oucher Scales |
| PedsQL | Paediatric Quality of Life Inventory |
| PROMIS tools | Patient-Reported Outcomes Measurement Information System |
| PFS | Piper Fatigue Scale |
| PIRS-20 | Pittsburgh Insomnia Rating Scale-20 |
| PSQI | Pittsburgh Sleep Quality Index |
| PMI | Pregnancy Mobility Index |
| PSS | Pruritus score scale |
| QLI | Quality of Life Index |
| RCSQ | Richards-Campbell Sleep Questionnaire |
| RMDQ | Roland-Morris Disability Questionnaires |
| SF-36 | Short Form Health Survey |
| SNOT-16 | Sino Nasal Outcome Tests 16 |
| SCI | Sleep Condition Indicator |
| SMHSQ | St Mary's Hospital Sleep Quality Questionnaire |
| STAI | State-Trait Anxiety Inventory |
| VSH | Verran and Snyder-Halpern Sleep Scale |
| VAS | Visual analogue scale |
| VAS-A | Visual Analogue Scale for Anxiety |
| VASF | Visual Analogue Scale for Fatigue |
| WHQ | Women’s Health Questionnaire |
| FACES | Wong-Baker FACES Pain Rating Scale |
| WHOQOL‑OLD | World Health Organization Quality of Life‑Older Adults Module |

1. In the protocol we reported that we would conduct sensitivity analyses excluding trials judged at high or unclear risk of bias. The terminology “Unclear risk of bias” has been replaced in ROB2 with “some concerns”. The approach described here is consistent with the protocol in that the sensitivity analyses were to be restricted to studies at low risk of bias. [↑](#footnote-ref-2)